ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0722

Myostatin in Idiopathic Inflammatory Myopathies: Seric Assessment and Disease Activity

Alexandrine Mahoudeau1, Céline Anquetil2, Nozomu Tawara1, Hossein Khademian1, Damien Amelin1, Yves Allenbach3 and Olivier Benveniste3, 1Center of Research in Myology, Sorbonne University, Paris, France, 2Center of Research in Myology, Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Clinical Immunology and Internal Medicine, Paris, France, 3Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Clinical Immunology and Internal Medicine, Paris, France

Meeting: ACR Convergence 2021

Keywords: cytokines, Disease Activity, Myositis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 7, 2021

Title: Muscle Biology, Myositis & Myopathies Poster (0683–0722)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: In Idiopathic Inflammatory Myopathies (IIM) disease activity is very difficult to assess and IIM may induce severe muscle damage, especially in immune-mediated necrotizing myopathies (IMNM). We hypothesize that myostatin, a negative regulator of muscle mass, could be a new biomarker of disease activity and/or muscle damage.

Methods: Prospective assessment of myostatin protein level in 447 IIM sera samples (dermatomyositis (DM), n=157; inclusion body myositis (IBM), n=72; immune-mediated necrotizing myopathies, n=125; anti-synthetase syndrome (ASyS), n=93) and 59 healthy donors (HD) was performed by ELISA. A gene transcript analysis was also carried out on 18 IIM muscle biopsies and 6 HD to analyze the expression of myostatin and myostatin pathway genes.

Results: IIM patients had lower myostatin circulating protein levels and gene expression compared to HD (2379 [1490; 3678] pg/ml vs 4281 [3169; 5787] pg/ml; p< 0.0001 and log2FC=-1.83; p=0.0005 respectively) (Fig1). Myostatin-related genes expression varied accordingly. Myostatin circulating levels were then assessed for each subgroups. Myostatin levels were lower in ASyS (3109 [1952; 4258] pg/ml; p=0,001), DM (2327 [1431; 3446] pg/ml; p< 0.0001), IMNM (2285 [1371; 3851] pg/ml; p< 0.0001) and IBM (2005 [1449; 2803] pg/ml; p< 0.0001) compared to HD (4281 [3169; 5787] pg/ml) (Fig2). Based on the Physician Global Activity score, inactive IIM patients had higher myostatin levels than active ones. This was the case for all IIM subgroups, except IMNM patients where low myostatin levels were maintained (2186 [1235; 3815] vs 2349 [1518; 3922] pg/ml; p=0.4) even during remission (Fig3).

Conclusion: Myostatin protein and RNA levels are decreased in all IIM patients and circulating protein levels are correlated with disease activity. Inactive ASyS and DM patients have higher level of myostatin than active patients. Myostatin could be a marker of disease activity in these two subgroups. However, IMNM patients do not have a significant increase in myostatin levels after disease remission. This observation may highlight a new pathological disease mechanism in IMNM patients.

Figure 1 : Quantification of circulating myostatin (A) and expression (Log2FC) of genes implicated in the myostatin pathway in IIM (B) compared to HD

FST: follisatin, MYOG: myogenin, MYF5: myogenic factor 5, INHBA: inhibin A, DCN: decorin, TRIM63: Tripartite Motif Containing 63, FBXO32: F-box Protein 32, MSTN: myostatin

Figure 2 : Circulating myostatin levels in IIM subgroups

Figure 3 : Circulating myostatin levels in active vs inactive IIM patients


Disclosures: A. Mahoudeau, None; C. Anquetil, None; N. Tawara, None; H. Khademian, None; D. Amelin, None; Y. Allenbach, None; O. Benveniste, None.

To cite this abstract in AMA style:

Mahoudeau A, Anquetil C, Tawara N, Khademian H, Amelin D, Allenbach Y, Benveniste O. Myostatin in Idiopathic Inflammatory Myopathies: Seric Assessment and Disease Activity [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/myostatin-in-idiopathic-inflammatory-myopathies-seric-assessment-and-disease-activity/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/myostatin-in-idiopathic-inflammatory-myopathies-seric-assessment-and-disease-activity/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology